

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/I92CB9200983EN.html>

Date: December 2022

Pages: 74

Price: US\$ 3,500.00 (Single User License)

ID: I92CB9200983EN

Abstracts

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 14 molecules. The latest report Integrin Beta 7 - Drugs In Development, 2022, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Pouchitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS) and Unspecified Gastrointestinal Disorders.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in
Therapeutics Development

AbbVie Inc

Aviara Pharmaceuticals Inc

Biora Therapeutics Inc

C4X Discovery Holdings Plc

Comera Life Sciences Inc

DICE Therapeutics Inc

Genentech USA Inc

Gilead Sciences Inc

Morphic Therapeutic Inc

Polpharma Biologics SA

Protagonist Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Zealand Pharma AS

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles

ABBV-1882 - Drug Profile

Product Description

Mechanism Of Action

Alpha4 Beta7 Integrin Inhibitor - Drug Profile

Product Description

Mechanism Of Action

etrolizumab - Drug Profile

Product Description
Mechanism Of Action
History of Events
GS-1427 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MORF-057 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Next generation alpha 4 beta 7 selective inhibitors - Drug Profile
Product Description
Mechanism Of Action
Oral alpha 4 beta 7 - Drug Profile
Product Description
Mechanism Of Action
PTG-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize Integrin Alpha 4 Beta 1 and Alpha 4 Beta 7 for
Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
vedolizumab biobetter - Drug Profile
Product Description
Mechanism Of Action
vedolizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action

ZP-10000 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development

Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Aviara Pharmaceuticals Inc, 2022

Pipeline by Biora Therapeutics Inc, 2022

Pipeline by C4X Discovery Holdings Plc, 2022

Pipeline by Comera Life Sciences Inc, 2022

Pipeline by DICE Therapeutics Inc, 2022

Pipeline by Genentech USA Inc, 2022

Pipeline by Gilead Sciences Inc, 2022

Pipeline by Morphic Therapeutic Inc, 2022

Pipeline by Polpharma Biologics SA, 2022

Pipeline by Protagonist Therapeutics Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by Zealand Pharma AS, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/I92CB9200983EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I92CB9200983EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

